---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003005"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:15:06.107867+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics 2024 net loss $16.5M, auditor flags going concern doubt

## Summary
- Net loss of $16.5M in 2024 vs $5.1M in 2023; operating expenses $12.6M.
- Cash used in operations $8.4M; cash and equivalents $1.2M at Dec 31, 2024.
- Auditor emphasizes substantial doubt about going concern due to recurring losses.
- Total liabilities $6.9M exceed assets $2.9M; capital deficiency of $4.0M.
- Financial statements retroactively adjusted for 1-for-15 reverse split effective July 28, 2025.

## SEC filing metadata
- accession: 0001178913-25-003005
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003005/0001178913-25-003005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003005/zk2533676.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003005
- JSON: https://secwatch.observer/filing/0001178913-25-003005.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.